Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?

Background: Several studies suggest that patients with KRAS-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most recently, KRAS 12c data suggest specific treatment for improving ORR and OS. There is a clear need for therapies specifically develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Karim, Nagla Abdel, Ullah, Asad, Pathrose, Peterson, Fathallah, Hassana, Perry, Ashley, Morris, John C., Wang, Jiang, Starnes, Sandra L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315614/
https://www.ncbi.nlm.nih.gov/pubmed/35877239
http://dx.doi.org/10.3390/curroncol29070379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315614/
https://www.ncbi.nlm.nih.gov/pubmed/35877239
http://dx.doi.org/10.3390/curroncol29070379

Ejemplares similares